High Flow Nasal Cannula for Stabilization of Extremely Premature Infants

Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Nov 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a High-Flow Nasal Cannula (a device that delivers oxygen) to help stabilize extremely premature infants right after they are born. The focus is on babies born between 25 and 27 weeks of pregnancy, weighing at least 500 grams. The researchers want to see if this method is safe and effective in providing the support these fragile infants need to breathe better immediately after birth. If the babies show signs of serious breathing problems, such as a slow heart rate or low oxygen levels, the medical team may switch to other treatments.

Currently, the trial is not yet recruiting participants, but eligible infants will be those who meet the age and weight criteria mentioned. If a baby is part of the trial, they will receive the High-Flow Nasal Cannula and gentle touch to stimulate their breathing. This study is important because it could help improve the care of very premature babies, giving them a better chance to thrive in their early days.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Preterm infants born between 25+0 and 27+6 gestational weeks
• • Weight above 500 grams
• Exclusion Criteria:
• • Previable rupture of membranes,
• • Congenital malformations previable
• • Acute intrauterine hypoxia.